||||||||||AOC-1020 / Avidity Biosci, AOC-Pompe Disease / Eli Lilly, Avidity Biosci AOC 1020: An Antibody Oligonucleotide Conjugate (AOC) in Development for the Treatment of FSHD (Virtual platform and E-Posters only) - Nov 5, 2022 - Abstract #WMS2022WMS_496; Single treatment also prevented FSHD-related muscle phenotype in this mouse model. Data presented provide support for AOC 1020 to enter the clinic for the treatment of FSHD by end of 2022.